Tiaki Therapeutics is a company developing therapeutics that target microglia, the immune cells of the brain, to address inflammatory-driven CNS disorders and protect cognitive function. The company offers a proprietary systems biology platform that preserves the complex biological interactions of brain cells and models the specific transcriptomic signature of neuroinflammation in dementia patients.